Delivery of rapamycin to dendritic cells using degradable microparticles

Journal of Controlled Release

Volumn 133, Issue 3, 2009, Pages 191-197

  Jhunjhunwala, S ^a,d   Raimondi, G ^b   Thomson, A W ^b,c   Little, S R ^a,c,d  

^a University of Pittsburgh   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Dendritic cells; Intracellular delivery; Microparticles; PLGA; Rapamycin

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; DENDRIMERS;

DENDRITIC CELLS; INTRACELLULAR DELIVERY; MICROPARTICLES; PLGA; RAPAMYCIN;

ENZYME ACTIVITY;

POLYGLACTIN; RAPAMYCIN;

ALKALINITY; ANIMAL CELL; ARTICLE; CONTROLLED DRUG RELEASE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; MICROENCAPSULATION; MOUSE; NONHUMAN; PARTICLE SIZE; PH; PHAGOCYTOSIS; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD40; ANTIGENS, CD86; APOPTOSIS; BIOLOGICAL AVAILABILITY; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELL SURVIVAL; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; HISTOCOMPATIBILITY ANTIGENS CLASS II; LACTIC ACID; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; PARTICLE SIZE; PHAGOCYTOSIS; POLYGLYCOLIC ACID; SIROLIMUS; SURFACE PROPERTIES;

EID: 58549112593     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.10.011     Document Type: Article

References (41)

1. Tantravahi J., Womer K.L., and Kaplan B. Why hasn't eliminating acute rejection improved graft survival?. Annual Review of Medicine 58 (2007) 369-385
2. Lechler R.I., Sykes M., Thomson A.W., and Turka L.A. Organ transplantation - how much of the promise has been realized. Nature Medicine 11 6 (2005) 605-613
3. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
4. Steinman R.M., Hawiger D., and Nussenzweig M.C. Tolerogenic dendritic cells. Annual Review of Immunology 21 (2003) 685-711
5. Krämer B.K., Böger C., Krüger B., Marienhagen J., Pietrzyk M., Obed A., Paczek L., Mack M., and Banas B. Cardiovascular risk estimates and risk factors in renal transplant recipients. Transplantation Proceedings 37 (2005) 1868-1870
6. Rubin R.H., Ikonen T., Gummert J.F., and Morris R.E. The therapeutic prescription for the organ transplant recipient: the linkage of imunosuppression and antimicrobial strategies. Transplant Infectious Diseases 1 (1999) 29-39
7. Duncan M.D., and Wilkes D.S. Transplant-related immunosuppression: a review of immunosuppression and pulmonary infections. Proceedings of American Thoracic Society 2 (2005) 449-455
8. Libby P., and Pober J.S. Chronic rejection. Immunity 14 (2001) 387-397
9. Sanchez A., Vila-Jata J.L., and Alonso M.J. Development of biodegradable microspheres and nanospheres for the controlled release of cyclosporin A. International Journal of Pharmaceutics 99 2-3 (1993) 263-273
10. Sanchez A., and Alonso M.J. Poly(D,L-lactide-co-glycolide) micro and nanospheres as a way to prolong blood/plasma levels of subcutaneously injected cyclosporin A. European Journal of Pharmaceutics and Biopharmaceutics 41 1 (1995) 31-37
11. Lamprechta A., Yamamoto H., Takeuchi H., and Kawashima Y. A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles. Journal of Controlled Release 104 (2005) 337-346
12. Italia J.L., Bhatt D.K., Bhardwaj V., Tikoo K., and Kumar M.N.V.R. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. Journal of Controlled Release 119 (2007) 197-206
13. Kahan B.D. Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation. Transplantation Proceedings 35 3 (2003) 37S-51S
14. Thliveris J.A., Solez K.S., and Yatscoff R.W. A comparison of the effects of rapamycin and cyclosporine on kidney and heart morphology in a rabbit heterotopic heart transplant model. Histology and Histopathology 10 2 (1995) 417-421
15. Thliveris J.A., and Yatscoff R.W. Effect of rapamycin on morphological and functional parameters in the kidney of the rabbit. Transplantation 59 3 (1995) 427-429
16. Hackstein H., Taner T., Zahorchak A.F., Morelli A.E., Logar A.J., Gessner J., and Thomson A.W. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 101 (2003) 4457-4463
17. Taner T., Hackstein H., Wang Z., Morelli A.E., and Thomson A.W. Rapamycin-treated, Alloantigen-pulsed host dendritic cells induce Ag-specific T cell regulation and prolong graft survival. American Journal of Transplantation 5 (2005) 228-236
18. Turnquist H.R., Raimondi G., Zahorchak A.F., Fischer R.T., Wang Z., and Thomson A.W. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. The Journal of Immunology 178 (2007) 7018-7031
19. Kohane D.S. Microparticles and nanoparticles for drug delivery. Biotechnology and Bioengineering 96 2 (2007) 203-209
20. Little S.R., Lynn D.M., Ge Q., Anderson D.G., Puram S.V., Chen J., Eisen H.N., and Langer R. Poly-b amino ester-containing microparticles enhance the activity of nonviral genetic vaccines. PNAS 101 (2004) 9534-9539
21. Wischke C., Borchert H.-H., Zimmermann J., Siebenbrodt I., and Lorenzen D.R. Stable cationic microparticles for enhanced model antigen delivery to dendritic cells. Journal of Controlled Release 114 (2006) 359-368
22. Zweers M.L.T., Engbers G.H.M., Grijpma D.W., and Feijen J. Release of anti-restenosis drugs from poly(ethylene oxide)-poly (DL-lactic-co-glycolic acid) nanoparticles. Journal of Controlled Release 114 (2006) 317-324
23. Thomas T.T., Kohane D.S., Wang A., and Langer R.S. Microparticulate formulations for the controlled release of interleukin-2. Journal of Pharmaceutical Sciences 93 5 (2004) 1100-1109
24. Martínez Gómez J.M., Csaba N., Fischer S., Sichelstiel A., Kündig T.M., Gander B., and Johansen P. Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis. Journal of Controlled Release (2008)
25. Yoshida M., and Babensee J.E. Molecular aspects of microparticle phagocytosis by dendritic cells. Journal of Biomaterial Science. Polymer Ed. 17 8 (2006) 893-907
26. Siepmann J., Elkharraz K., Siepmann F., and Klose D. How autocatalysis accelerates drug release from PLGA-based microparticles: a quantitative treatment. Biomacromolecules 6 (2005) 2312-2319
27. Rothstein S.N., Federspiel W.J., and Little S.R. A simple model framework for the prediction of controlled release from bulk eroding polymer matrices. Journal of Materials Chemistry 18 (2008) 1873-1880
28. Fischer S., Allmen E.U., Waeckerle-Men Y., Groettrup M., Merkle H.P., and Gander M. The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles. Biomaterials 28 (2007) 994-1004
29. Walter E., Dreherb D., Kokc M., Thiele L., Kiama S.G., Gehr P., and Merkle H.P. Hydrophilic poly(DL-lactide-co-glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells. Journal of Controlled Release 76 (2001) 149-168
30. Lecaroz C., Gamazo C., Renedo M.J., and Blanco-Prieto M.J. Biodegradable micro- and nanoparticles as long-term delivery vehicles for gentamicin. Journal of Microencapsulation 23 7 (2006) 782-792
31. Lecaroz M.C., Blanco-Prieto M.J., Campanero M.A., Salman H., and Gamazo C. Poly(D,L-lactide-coglycolide) particles containing gentamicin: pharmacokinetics and pharmacodynamics in Brucella melitensis-infected mice. Antimicrobial Agents and Chemotherapy 51 4 (2007) 1185-1190
32. Lee W.K., Park J.Y., Yang E.H., Suh H., Kim S.H., Chung D.S., Choi K., Yang C.W., and Park J.S. Investigation of the factors influencing the release rates of cyclosporin A-loaded micro- and nanoparticles prepared by high-pressure homogenizer. Journal of Controlled Release 84 (2002) 115-123
33. Haddadi A., Elamanchili P., Lavasanifar A., Das S., Shapiro J., and Samuel J. Delivery of rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells. Journal of Biomedical Materials Research 84A (2008) 885-898
34. Newman K.D., Elamanchili P., Kwon G.S., and Samuel J. Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. Journal of Biomedical Materials Research 60 3 (2002) 480-486
35. Tabata Y., and Ikada Y. Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo- and copolymers. Journal of Biomedical Materials Research 22 (1988) 837-858
36. Morelli A.E., and Thomson A.W. Tolerogenic dendritic cells and the quest for transplant tolerance. Nature Reviews Immunology 7 8 (2007) 610-621
37. Bluestone J.A., Thomson A.W., Shevach E.M., and Weiner H.L. What does the future hold for cell-based tolerogenic therapy?. Nature Reviews Immunology 7 8 (2007) 650-654
38. McCurry K.R., Colvin B.L., Zahorchak A.F., and Thomson A.W. Regulatory dendritic cell therapy in organ transplantation. Transplant International 19 7 (2006) 525-538
39. Woltman A.M., Fijter J.W.D., Kamerling S.W.A., van der Kooij S.W., Paul L.C., Daha M.R., and Kooten C.V. Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood 98 1 (2001) 174-181
40. Phillips B., Nylander K., Harnaha J., Machen J., Lakomy R., Styche A., Gillis K., Brown L., Lafreniere D., Gallo M., Knox J., Hogeland K., Trucco M., and Giannoukakis N. A microsphere-based vaccine prevents and reverses new-onset autoimmune diabetes. Diabetes 57 6 (2008) 1544-1555
41. Hackstein H., and Thomson A.W. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nature Reviews Immunology 4 1 (2004) 24-34